VRDN Stock Summary and Trading Ideas (Viridian Therapeutics | NASDAQ:VRDN)

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

Viridian Therapeutics trades on the NASDAQ stock market under the symbol VRDN.

As of March 5, 2025, VRDN stock price climbed to $15.28 with 723,069 million shares trading.

VRDN has a beta of 2.21, meaning it tends to be more sensitive to market movements. VRDN has a correlation of 0.16 to the broad based SPY ETF.

VRDN has a market cap of $1.21 billion. This is considered a Small Cap stock.

Last quarter Viridian Therapeutics reported $72,000 in Revenue and -$.81 earnings per share. This beat revenue expectation by $23,230 and exceeded earnings estimates by $.19.

In the last 3 years, VRDN traded as high as $39.00 and as low as $9.47.

The top ETF exchange traded funds that VRDN belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.

VRDN has underperformed the market in the last year with a return of -19.8%, while the SPY ETF gained +15.2%. In the last 3 month period, VRDN fell short of the market, returning -23.4%, while SPY returned -3.7%. However, in the most recent 2 weeks VRDN has outperformed the stock market by returning -3.6%, while SPY returned -4.6%.

VRDN support price is $14.61 and resistance is $15.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VRDN shares will trade within this expected range on the day.